摘要
目的探究恩替卡韦对乙肝肝硬化代偿期患者乙型肝炎病毒DNA(HBV-DNA)水平及肝功能的改善作用效果,为恩替卡韦的合理应用提供指导建议。方法随机选取本院2016年11月至2018年9月收治的乙肝肝硬化代偿期患者100例为研究对象,根据治疗方法的不同将其分为A组、B组,各50例。A组患者采取阿德福韦酯片治疗,B组患者采取恩替卡韦治疗,比较两组治疗效果。结果治疗后,B组患者总有效率(96.00%)高于A组(80.00%),对比差异具有统计学意义(P<0.05);B组患者HBV-DNA水平低于A组,对比差异具有统计学意义(P<0.05);B组患者肝功能各项指标水平改善程度高于A组,对比差异具有统计学意义(P<0.05)。结论对乙肝肝硬化代偿期患者予以恩替卡韦治疗,疗效确切,利于降低患者HBV-DNA水平及促进患者肝功能的恢复,值得优选。
Objective To investigate the effect of entecavir on the level of hepatitis B virus DNA(HBV-DNA) and liver function in patients with compensated hepatitis B cirrhosis, and to provide guidance for the rational application of entecavir. Methods A total of 100 patients with compensated hepatitis B cirrhosis were enrolled in our hospital from November 2016 to September 2018. They were divided into group A and group B according to different treatment methods, with 50 cases in each group. Patients in group A were treated with adefovir dipivoxil tablets, and patients in group B were treated with entecavir to compare the effects of the two groups. Results After treatment, the total effective rate(96.00%) was higher in group B than in group A(80.00%), and the difference was significant(P<0.05). The level of HBV-DNA in group B was lower than that in group A, and the difference was significant(P<0.05). The improvement of liver function indexes in group B was higher than that in group A, and the difference was significant(P<0.05). Conclusion Entecavir treatment for patients with compensated hepatitis B cirrhosis is effective, which is beneficial to reduce the level of HBV-DNA and promote the recovery of liver function in patients.
作者
何景春
He Jingchun(Department of Infectious,Chifeng City Infectious Disease Prevention Hospital,Chifeng,Inner Mongolia,024000,China)
出处
《当代医学》
2020年第8期94-96,共3页
Contemporary Medicine